William Blair launched coverage of Calithera Biosciences (NASDAQ:CALA) with an “outperform” rating. The stock closed at $16.05 on Oct. 5.Read More
Closely-held Contextual Genomics has teamed up with CORE Diagnostics to introduce its Find-It genomic test in India.Read More
Tetra Bio-Pharma (OTCQB:TBPMF; CSE:TBP) has signed a letter of intent with Constance Therapeutics of San Francisco for the clinical development and commercialization in Canada of its signature medicinal cannabis extract products.Read More
H.C. Wainwright initiated coverage of Swiss-based ObsEva (NASDAQ:OBSV) with a “buy” rating and $27 price target. The stock closed at $7.50 on June 29.Read More
3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) has processed and analyzed the first batch of blood samples for the PRECISE prostate cancer trial at its new laboratory and corporate headquarters in the MaRS Discovery District in Toronto.Read More
Leerink resumed coverage of Calithera Biosciences (NASDAQ:CALA) with an “outperform” rating and a $16 price target, saying the company is well positioned to execute with multiple sources of upside. The stock closed at $11.55 on March 31.Read More
Profound Medical (OTCQX:PRFMF; TSXV:PRN) has successfully completed the first sale of a TULSA-PRO system in Finland to the Turku University Hospital, in collaboration with Royal Philips, who is working in partnership with Profound to commercialize the TULSA-PRO system in Europe.Read More
Ladenburg Thalmann launched coverage of Leap Therapeutics (NASDAQ: LPTX) with a “buy” rating and $18 price target. The stock closed at $7.85 on March 6.Read More
Roth Capital Partners has reestablished estimates, a ‘buy” rating, and $17 price target for Aduro Biotech (NASDAQ:ADRO) based on a sum-of-parts, probability-adjusted net present value analysis. The stock closed at $11 on March 6.Read More
Stifel downgraded Argos Therapeutics (NASDAQ:ARGS) to “hold” from “buy” and slashed its price target to $1.40 from $10 after an independent data monitoring committee (IDMC) recommended discontinuation of the ADAPT Phase 3 trial of AGS-003 in metastatic renal cell carcinoma (RCC) patients.Read More
Dr. Sabine Mai, a co-founder and principle inventor of 3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0), will present on Feb. 21 at the International Molecular Medicine Tri-Conference in San Francisco, results of a prospective blood-based prostate cancer pilot study using the company’s TeloView software platform.Read More
Roth Capital Partners has resumed coverage of Viralytics (ASX:VLA; OTCQX:VRACY) with a “buy” rating and AUD$2 price target. The stock closed at AUD$1.05 on Jan. 30.Read More
Closely-held Turnstone Biologics has completed a $41.4-million series B financing led by new investor, OrbiMed, with participation from another new investor, F-Prime Capital Partners, and existing investors, FACIT and Versant Ventures, which led Turnstone’s series A financing.
The series B financing takes place less than a year from the series A that allowed the company to progress its lead asset through an initial Phase 1/2 trial to establish safety, maximum tolerated dose and initial evidence of immunological activity in patients with advanced solid and metastatic tumors.Read More
Leerink resumed coverage of Kura Oncology (NASDAQ:KURA) with an “outperform” rating and $15 price target. The stock closed at $5.60 on Wednesday.
“We view Kura's lead pipeline program, tipifarnib (a farnesyltransferase inhibitor) as a safe and active drug,” writes analyst Jonathan Chang.Read More
H.C. Wainwright analyst Swayampakula Ramakanth has assumed coverage of Celsion (NASDAQ:CLSN) with a “buy” rating and $3 price target. The stock closed at $1.30 on Monday.
Celsion has developed two cancer therapeutic platforms: LTSL for the delivery of chemotherapies and TheraPlas for the delivery of therapeutic DNA, RNA or proteins, both of which allow drugs to be delivered locally at high concentrations for greater therapeutic benefit and lower toxicity.Read More
Roth Capital Partners has initiated coverage on Biocept (NASDAQ:BIOC) with a “buy” rating and target price of $1.20. The stock closed at 63 cents on Monday.
“Through its proprietary technology platform capable of assaying both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), strong IP portfolio, notable collaborations with leading cancer institutions, and building commercial momentum, we believe Biocept is uniquely positioned as a leader in the emerging field of liquid biopsy and personalized medicine,” writes analyst Chris Lewis.Read More
ARIAD Pharmaceuticals (NASDAQ:ARIA) has initiated a Phase 1/2 clinical trial of AP32788, an investigational tyrosine kinase inhibitor (TKI) designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in EGFR or HER2.
AP32788 targets tumors driven by EGFR or HER2 kinases and was designed to achieve selective inhibition of these kinases with exon 20 mutations. There are currently no approved targeted treatment options available for the approximately 4% to 9% of EGFR-mutated lung tumors with exon 20 insertion mutations in NSCLC patients.Read More
Stifel has upgraded Exelixis (NASDAQ:EXEL) to “buy” from “hold” with a price target of $7. The stock closed at $4.05 on Friday.
Exelixis is developing small molecule therapies for the treatment of cancer and is focusing its development and commercialization efforts primarily on cabozantinib, an internally discovered inhibitor of multiple receptor tyrosine kinases.Read More
Closely-held Soricimed Biopharma has announced positive top-line results from a Phase 1 open-label, dose escalation study of its first-in-class peptide, SOR-C13, in subjects with advanced solid tumor cancers.
The primary goal of the study was to assess safety and tolerability of SOR-C13 in subjects with advanced carcinomas commonly known to express the TRPV6 channel and who had failed all previous anti-cancer treatments. SOR-C13 is the first drug candidate targeting TRPV6 to enter human clinical trials.Read More